Parsatuzumab

Parsatuzumab (INN) is a humanized monoclonal antibody designed for the treatment of cancer.

It acts as an immunomodulator and binds to EGFL7.

[1] This drug was developed by Genentech/Roche.

This monoclonal antibody–related article is a stub.

You can help Wikipedia by expanding it.